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Real world experience of secukinumab treatment for ankylosing spondylitis at 
the Royal National Hospital for Rheumatic Diseases, Bath. 
 
Key points 
1. Secukinumab was efficacious for improving short-term mean disease activity 
and function in our cohort of ankylosing spondylitis patients, regardless of 
whether used as the first, second, or third line biologic disease-modifying drug. 
2. There were very low rates of discontinuation due to side effects in our cohort of 
secukinumab-treated ankylosing spondylitis patients. 
 
Abstract 
We reviewed our experience of treating ankylosing spondylitis patients with the IL-17 
inhibitor secukinumab at the Royal National Hospital for Rheumatic Diseases, Bath. 
76 patients were included, of whom secukinumab was the first line biologic drug used 
in 24, second line in 23 and third line in 29 patients, respectively. Only 5 patients 
discontinued the drug due to side effects before their first outpatient review, including 
1 new case of inflammatory bowel disease. Significant improvements were seen in all 
disease outcome measures in patients receiving secukinumab as their first-line 
biologic agent, with a trend to improved mean BASDAI and BASFI even in patients 
receiving it as a second- or third-line biologic agent. This real world analysis adds to 
the evidence recommending secukinumab as a largely safe and effective treatment 
for ankylosing spondylitis. 
 
Introduction/ objectives 
Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting the spine, 
sacro-iliac and peripheral joints. Associated extra-articular manifestations include 
acute anterior uveitis, psoriasis and inflammatory bowel disease. There is increasing 
evidence that persistent spinal inflammatory disease may lead to increased new bone 
formation and damage in AS [1, 2]. 
The phase III MEASURE I study demonstrated the efficacy of secukinumab, a fully 
humanised monoclonal antibody against IL-17A, in reducing disease activity and 
improving AS symptoms in a clinical trial setting [3]. The National Institute for Health 
and Care Excellence (NICE) recommended secukinumab for the treatment of AS 
which is refractory to conventional therapy in 2016 [4]. 
The aim of our study is to retrospectively evaluate the efficacy and safety of 
secukinumab treatment in a real world cohort of AS patients, treated at the Royal 
National Hospital for Rheumatic Diseases (RNHRD) in Bath, United Kingdom. 
 
Methods 
Study design and patients 
We performed a single-centre retrospective analysis in all AS patients treated with 
secukinumab at RNHRD who consented to inclusion in the BathSpA biobank. Data 
was obtained from outpatient clinic appointments as part of routine clinical practice. 
No additional data gathering was performed for the purpose of this study. There were 
no exclusion criteria.  
 
Procedures and end points 
In order to assess the efficacy of secukinumab, outcome measures were obtained at 
baseline and first follow-up assessment.  We aimed for first follow-up after 16 weeks 
of treatment, however this duration varied between patients, reflecting our real world 
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experience. Outcome measures included Bath Ankylosing Spondylitis Disease Activity 
Index (BASDAI),  Bath Ankylosing Spondylitis Functional Index (BASFI), Ankylosing 
Spondylitis Quality of Life score (ASQOL), the Functional Assessment of Chronic 
Illness Therapy score (FACIT), EQ5D visual analogue score (EQ5D-VAS), and 
Jenkins Sleep Evaluation Questionnaire (JSEQ). We reported the absolute difference 
in mean outcome measures between baseline and first follow-up assessment after 
treatment (aiming for 16 weeks). As per NICE guidelines [4], secukinumab was 
deemed ineffective and discontinued if the patient failed to achieve an improvement 
by 2 points (or 50%) in both the BASDAI and spinal pain visual analogue score at this 
assessment. 
In order to assess the safety of secukinumab, we have reported all patients who 
discontinued during longitudinal follow-up and the reason for discontinuation.  
 
Statistical analysis 
A T-test was used to calculate the two-tailed significance of the absolute mean 
difference in outcome measures following treatment, from which 95% confidence 
intervals were calculated. Mean differences with p-values less than 0.05 and 0.01 
respectively were regarded as statistically significant. A sub-group analysis was 
subsequently performed to identify differences between patients who received 
secukinumab as the first, second or third line biologic disease modifying drug 




76 patients (52 male, 24 female) were included. The age at diagnosis ranged from 19 
to 42 years (mean age 27.3 years), with a mean disease duration of 25.3 years prior 
to starting secukinumab (range 0.8 to 41.0 years). The mean (and range of lowest; 
highest) baseline scores were as follows: BASDAI 6.7 (1.2; 9.0), BASFI 6.5 (1.0; 10.0), 
ASQOL 10.2 (2.0; 18.0), BASMI 3.2 (0.4; 7.4). Secukinumab was the first line 
bDMARD in 24 patients (17 male, 7 female), second line bDMARD in 24 patients (17 
male, 7 female) and third line bDMARD in 28 patients (18 male, 10 female). bDMARDs 
prescribed prior to secukinumab are summarised in table 1 for patients receiving 
secukinumab second-line (part a) and third-line (part b). 
 
Table 1: Summary of previous bDMARDs received by patients prior to initiation of 
secukinumab. 
 
a) Secukinumab received as second-line bDMARD (n=24): 
 
1st bDMARD Number % 
Adalimumab 10 41.7 
Etanercept 6 25.0 
Etanercept (biosimilar) 2 8.3 
Golimumab 3 12.5 
Certolizumab pegol 2 8.3 










b) Secukinumab received as third-line bDMARD (n=28): 
 
1st bDMARD Number % 2nd bDMARD Number % 
Adalimumab 11 39.3 Adalimumab 13 46.4 
Etanercept 10 35.7 Etanercept 9 32.1 
Etanercept 
(biosimilar) 
1 3.6 Etanercept 
(biosimilar) 
2 7.1 
Golimumab 2 7.1 Golimumab 1 3.6 
Certolizumab 
pegol 
2 7.1 Certolizumab 
pegol 
2 7.1 
Infliximab  1 3.6 Ustekinumab 1 3.6 
Tocilizumab 1 3.6    
 
The mean delay between the baseline and first follow-up assessment of AS outcome 
measures was 25 weeks. 
 
Clinical efficacy 
The primary measures of clinical efficacy are summarised in table 2; parts a, b and c. 
Overall, the treatment efficacy of secukinumab was greater when given as a first line 
bDMARD, where significant improvements in all outcome measures were 
demonstrated. Nonetheless, secukinumab resulted in significant improvements in 
mean BASDAI when given as a second line bDMARD and mean BASFI when given 
as a third line bDMARD. 
 
Table 2: Efficacy outcomes for patients receiving secukinumab for AS demonstrated 
by mean difference between baseline and first follow-up review. 'Significant 
differences: * p <.05; ** p < .01. 
Abbreviations included are BASDAI: Bath Ankylosing Spondylitis Disease Activity 
Score; BASFI: Bath Ankylosing Spondylitis Functional Index; ASQoL: Ankylosing 
Spondylitis Quality of Life score; FACIT: Functional Assessment of Chronic Illness 
Therapy score; EQ5D-VAS: EQ5D visual analogue score; JSEQ: Jenkins Sleep 
Evaluation Questionnaire. 
 
















BASDAI 6.58 4.21 2.37 (36%) 0.73; 4.01 0.008** 
BASFI 6.91 4.84 2.07 (30%) 0.64; 3.49 0.009** 
ASQoL 12.56 7.00 5.56 (44%) 0.83; 10.28 0.027* 
FACIT 21.63 32.38 -10.75 (-
50%) 
-23.15; 1.65 0.079 
EQ5D-VAS 43.64 68.64 -25.00 (-
57%) 
-47.38; -2.62 0.032* 
JSEQ 13.20 8.00 5.20 (39%) 0.62; 9.78 0.030* 






















BASDAI 6.61 4.67 1.94 (29%) 0.68; 3.21 0.006** 
BASFI 5.75 5.09 0.66 (11%) -0.31; 1.63 0.164 
ASQoL 12.73 11.60 1.13 (9%) -3.66; 5.91 0.595 
FACIT  21.60 22.00 -0.40 (-2%) -6.33; 5.53 0.861 
EQ5D-VAS 53.00 49.17 3.83 (7%) -4.70; 12.37 0.301 
JSEQ 13.22 10.22 3.00 (23%) -0.94; 6.94 0.117 
 
















BASDAI 5.66 4.89 0.77 (14%) -0.20; 1.74 0.114 
BASFI 5.85 5.02 0.83 (14%) 0.06; 1.61 0.036* 
ASQoL 10.78 11.27 -0.49 (-5%) -2.71; 1.73 0.644 
FACIT  23.21 26.21 -3.00 (-13%) -10.59; 4.59 0.409 
EQ5D-VAS 54.58 52.92 1.67 (3%) -11.00; 14.33 0.777 
JSEQ 12.39 12.78 -0.39 (-3%) -3.03; 2.25 0.760 
 
In total, 16 patients discontinued treatment due to inefficacy. Of these, 4/24 (16.7%) 
were receiving secukinumab as the first line bDMARD, 6/24 (25%) were second line 
and 6/28 (21.4%) were third line. The previous bDMARDs used in the second and third 
line secukinumab non-responders and reasons for discontinuation of those drugs for 
each patient are listed in Table 3, parts a and b. 
 
Table 3: Summary of previous bDMARDs received by secukinumab non-responders 
and primary reason for discontinuation of those drugs: 
 
a) Secukinumab as second-line bDMARD (n=6): 
Patient 1st line bDMARD Reason for discontunation 
1 Etanercept Family planning 
2 Golimumab Side effects 
3 Etanercept Inefficacy 
4 Etanercept Inefficacy 
5 Adalimumab Inefficacy 











b) Secukinumab as third-line bDMARD (n=6): 








1 Etanercept Inefficacy Adalimumab Inefficacy 
2 Golimumab Side effects Adalimumab Inefficacy 
3 Etanercept Inefficacy Adalimumab Recurrent 
infections 
4 Adalimumab Recurrent 
infections 
Etanercept Inefficacy 
5 Etanercept Inefficacy Adalimumab Inefficacy 






Of the 76 patients receiving secukinumab, 5 (6.6%) discontinued due to side effects. 
These include 1 de novo case of Crohn’s disease, along with one case each of vertigo, 
low mood, mouth ulceration and sensory disturbance. 
 
Discussion 
Our real world experience of treating AS patients with secukinumab demonstrates a 
clear trend towards improved mean BASDAI and BASFI scores after six months’ 
treatment, regardless of whether it is used as a first, second or third line bDMARD. 
21.1% of patients discontinued secukinumab at the follow-up assessment due to 
inefficacy as defined by NICE guidelines (16.7% in bDMARD naïve versus 23.5% in 
previous bDMARD-treated patients).  Although not a like-for-like comparison of 
efficacy, this contrasts with the 39% of secukinumab-treated patients who failed to 
achieve 20% improvement as per Assessment of SpondyloArthritis international 
Society criteria (ASAS20 response) after 16 weeks in the MEASURE I study [3]. 
Relatively few patients discontinued secukinumab due to adverse effects, although we 
did experience one newly diagnosed case of inflammatory bowel disease. Further 
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